Tharimmune, Inc. | Finanzwire

Basculer en Français

8621	Companies
142926	Keywords
78688	Articles
76379	Press releases

Home
Companies
Tharimmune, Inc.

BRIEF

published on 04/15/2025 at 15:05, 6 days 10 hours ago

Tharimmune Enhances Board with Vincent LoPriore Appointment

Biotechnology Board Appointment Financial Strategy Tharimmune Vincent LoPriore
PRESS RELEASE

published on 04/15/2025 at 15:00, 6 days 10 hours ago

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors
Tharimmune, Inc. appoints Vincent LoPriore to its Board of Directors to bolster strategic leadership and drive growth in immunology and oncology. The move reflects the company's commitment to enhancing its leadership team with experienced financial professionals

Board Of Directors Oncology Tharimmune, Inc. Immunology Vincent LoPriore
BRIEF

published on 04/07/2025 at 14:05, 14 days 11 hours ago

Tharimmune Unveils Promising Data on New Biologic Treatments

Cancer Treatment Tharimmune Biologics EpiClick Technology HS1940 HS3215
PRESS RELEASE

published on 04/07/2025 at 14:00, 14 days 11 hours ago

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
Tharimmune, Inc. announces preclinical data on novel dual-target biologics HS1940 and HS3215 using EpiClick™ Technology to address cancer treatment needs

Cancer Treatment Tharimmune Inc. Preclinical Data EpiClick Technology Dual-target Biologics
BRIEF

published on 03/31/2025 at 14:05, 21 days 11 hours ago

Tharimmune Receives FDA Nod for TH104 NDA Pathway

TH104 FDA Feedback Tharimmune 505(b)(2) Pathway Opioid Prophylaxis
PRESS RELEASE

published on 03/31/2025 at 14:00, 21 days 11 hours ago

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
Tharimmune received positive feedback from the FDA on the 505(b)(2) NDA submission for TH104 buccal film for opioid prophylaxis. Company progressing CMC plan for NDA requirements

Buccal Film FDA Feedback Tharimmune 505(b)(2) NDA Submission CMC Plan
BRIEF

published on 03/24/2025 at 13:05, 28 days 12 hours ago

Tharimmune Reports Positive Preclinical Results for Oral Antibody TH023

Tharimmune Preclinical Results Infliximab TH023 Oral Antibody
PRESS RELEASE

published on 03/24/2025 at 13:00, 28 days 12 hours ago

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Tharimmune, Inc. announces positive preclinical results for novel oral antibody, TH023, a potential game-changer for inflammatory disease treatment. Company aims for patient-friendly administration and improved efficacy

Tharimmune Inc. Immunology Preclinical Results Inflammatory Disease Oral Antibody
BRIEF

published on 03/04/2025 at 13:05, 1 month 17 days ago

Tharimmune Expands Pipeline with HS1940 and HS3215 Biologics

Cancer Treatment Tharimmune Inc. HS1940 EpiClick Technology Pipeline Expansion
PRESS RELEASE

published on 03/04/2025 at 13:00, 1 month 17 days ago

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
Tharimmune, Inc. expands product pipeline with HS1940, a multispecific biologic targeting PD-1 and VEGF epitopes to enhance cancer treatment options. EpiClick™ Technology enables creation of novel therapeutics

Cancer Treatment Tharimmune HS1940 EpiClick Technology Multispecific Biologic

1 2 ... 5

Accesswire

Published on 04/22/2025 at 01:00, 20 minutes ago

Forte Group Closes Strategic Initiatives to Strengthen Financial Position
Published on 04/21/2025 at 23:00, 2 hours 20 minutes ago

Revolve to Present at the Planet MicroCap Showcase
Published on 04/21/2025 at 22:30, 2 hours 50 minutes ago

Zimtu Capital Corp. Announces Proposed Share Consolidation
Published on 04/21/2025 at 21:45, 3 hours 35 minutes ago

Stillwater Critical Minerals Announces Grant of Long-Term Performance Incentives and Restricted Share Units
Published on 04/21/2025 at 20:45, 4 hours 35 minutes ago

NV Gold Announces Shares for Debt Transaction

View all ACCESSWIRE

EQS Group

Published on 04/21/2025 at 17:48, 7 hours 31 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 04/21/2025 at 17:48, 7 hours 32 minutes ago

Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 04/21/2025 at 17:47, 7 hours 32 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Greencore Group plc
Published on 04/21/2025 at 17:46, 7 hours 33 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Urban Logistics REIT plc
Published on 04/21/2025 at 17:45, 7 hours 34 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc

Les Echos

Published on 04/18/2025 at 17:45, 3 days 7 hours ago

Saint-Gobain once again featured on CDP’s “Climate A List”
Published on 04/18/2025 at 11:16, 3 days 14 hours ago

Disclosure of transactions in own shares from April 14 to April 17, 2025
Published on 04/18/2025 at 07:00, 3 days 18 hours ago

Invitation to the Annual and Extraordinary General Meeting of Shareholders
Published on 04/17/2025 at 19:10, 4 days 6 hours ago

Covivio - Description of the share buy-back program authorized by the Combined Ordinary and Extraordinary Shareholders’ Meeting held on 17 April 2025
Published on 04/17/2025 at 18:00, 4 days 7 hours ago

Accor expands its network in the Americas with the addition of 17 hotels

View all LES ECHOS COMFI WIRE